newsfilter
← Latest News
PR Newswire·

China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

  • China SXT Pharmaceuticals Inc. announced the termination of its registered direct offering dated October 8, 2026.
  • The Company & purchasers executed a termination letter agreement ending the additional purchase right under Section 2.4 of the securities purchase agreement.
  • The terminated right allowed purchasers to buy up to $12 million of Class A ordinary shares & pre-funded warrants within 30 days of the Offering closing.
  • Purchasers no longer hold rights to make additional purchases under Section 2.4, while all other agreement provisions remain in full force.
  • The termination does not impact the securities already issued during the Offering.
  • China SXT Pharmaceuticals Inc. is a Taizhou-based company founded in 2005 focusing on processed traditional Chinese medicine.